Cxbladder - Information for Clinicians
Cxbladder is a family of non-invasive molecular diagnostic laboratory tests optimized to help you assess the probability that your patient has bladder cancer, giving you actionable results that can make a meaningful difference in their treatment.
More reliable and objective than many other urine-based tests, Cxbladder utilizes high sensitivity and Negative Predictive Value to provide accurate results.
Cxbladder provides actionable results to facilitate the early detection of bladder cancer by either helping to rule out the disease or to complement other diagnostic procedures and tests.
Non-invasive and pain free, Cxbladder provides a complete sampling system for collection of the patient’s urine sample and shipment to our laboratory.
Over ten years of research has identified five specific messenger RNA (mRNA) biomarkers that represent a bladder cancer signature. Cxbladder has been validated by a large multicenter clinical studies published in a highly respected peer reviewed journals.
Overview of Tests
Cxbladder is a non-invasive test for the detection of bladder cancer that gives you actionable results that can make a meaningful difference in your patient's treatment.
The Cxbladder technology comprises proprietary, accurate molecular testing of genomic biomarkers (mRNA) from a small volume of patients’ urine, and patient clinical characteristics enabling the non-invasive detection of bladder and other urinary tract cancers (urothelial carcinoma).
The Cxbladder suite of products provides a ‘one-stop shop’ for clinicians in the primary detection and post-treatment management of urothelial carcinoma (UC).
Learn about Cxbladder product suite - Triage, Detect, and Monitor.
Cxbladder gives you actionable results that can make a meaningful difference in your patient's diagnosis and treatment.
The Cxbladder cancer detection tests have been validated by large multicenter clinical studies. Cxbladder is more reliable and objective than many other urine-based cancer detection tests. With its high sensitivity, Cxbladder makes an effective adjunct to cystoscopy.
IMPORTANT UPDATE FOR UROLOGISTS: Sia Daneshmand M.D. (@siadaneshmand) reviews recent @EUPlatinum study comparing perf. of Cxbladder urine biomarker test with urine cytology, and its utility in resolving inconclusive cytology or cystoscopy: https://t.co/lpzvbKMoSs #bladdercancer pic.twitter.com/meiHU4xtjT— Cxbladder (@Cxbladder) October 30, 2019
Cxbladder was developed by a company whose passion and focus is cancer diagnostics and prognostics to improve patient outcomes. See our full list of clinical publications.
Pacific Edge is responsible for the development and determination of the performance characteristics for Cxbladder. Because Cxbladder is a Laboratory Developed Test (LDT), Cxbladder has not been cleared or approved by the US Food and Drug Administration (FDA).
Diagnosing bladder cancer
Dr Rod Studd discusses the guidelines, issues and technologies for diagnosing UC in patients presenting with hematuria in primary care.
Comprehensive solution for your clinical needs
Cxbladder gives you actionable results that can make a meaningful difference in your patient’s diagnosis and treatment.Learn more about Cxbladder’s clinical applications
Cxbladder sampling process
Cxbladder is a suite of non-invasive tests that is easy and straightforward to use.Watch the instructional video here
Talk to a Rep
Contact us by phone or email, or fill out an online form and a Cxbladder representative will get back to you.Complete an information request form today